Can-Fite BioPharma (NYSE:CANF) Downgraded by StockNews.com

StockNews.com cut shares of Can-Fite BioPharma (NYSE:CANF) from a hold rating to a sell rating in a report published on Monday.

Separately, EF Hutton Acquisition Co. I upgraded shares of Can-Fite BioPharma to a “strong-buy” rating in a report on Wednesday, July 17th.

Can-Fite BioPharma Price Performance

CANF opened at $2.70 on Monday. The firm has a market capitalization of $9.56 million, a price-to-earnings ratio of -1.51 and a beta of 1.41. The company’s 50 day simple moving average is $2.27 and its two-hundred day simple moving average is $2.49. Can-Fite BioPharma has a 1-year low of $1.81 and a 1-year high of $4.69.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Armistice Capital LLC increased its position in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 518,853 shares of the company’s stock after purchasing an additional 136,055 shares during the period. Armistice Capital LLC owned 14.66% of Can-Fite BioPharma worth $1,339,000 at the end of the most recent quarter. Institutional investors and hedge funds own 21.00% of the company’s stock.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.